These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 36576372)
21. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
23. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326 [TBL] [Abstract][Full Text] [Related]
24. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633 [TBL] [Abstract][Full Text] [Related]
25. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210 [TBL] [Abstract][Full Text] [Related]
26. The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review. Ezhumalai B; Modi R; Panchanatham M; Kaliyamoorthy D Indian Heart J; 2024; 76(4):229-239. PubMed ID: 39009078 [TBL] [Abstract][Full Text] [Related]
27. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107 [TBL] [Abstract][Full Text] [Related]
28. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy. Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551 [TBL] [Abstract][Full Text] [Related]
29. Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials. Suebsaicharoen T; Chunekamrai P; Yingchoncharoen T; Tansawet A; Issarawattana T; Numthavaj P; Thakkinstian A Open Heart; 2023 Nov; 10(2):. PubMed ID: 37940331 [TBL] [Abstract][Full Text] [Related]
30. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917 [TBL] [Abstract][Full Text] [Related]
31. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study. Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608 [TBL] [Abstract][Full Text] [Related]
33. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159 [TBL] [Abstract][Full Text] [Related]
34. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
35. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. Savarese G; Lindberg F; Christodorescu RM; Ferrini M; Kumler T; Toutoutzas K; Dattilo G; Bayes-Genis A; Moura B; Amir O; Petrie MC; Seferovic P; Chioncel O; Metra M; Coats AJS; Rosano GMC Eur J Heart Fail; 2024 Jun; 26(6):1408-1418. PubMed ID: 38515385 [TBL] [Abstract][Full Text] [Related]